Direct oral anticoagulants reduce cancer-associated venous thromboembolism recurrence

Direct oral anticoagulants significantly reduced risk for recurrence of cancer-associated venous thromboembolism compared with dalteparin among patients with cancer, according to study results published in Mayo Clinic Proceedings.
The findings suggest direct oral anticoagulants (DOACs) should be considered the standard-of-care treatment for adults with cancer-associated VTE, researchers noted.
“The landmark CLOT trial established low-molecular-weight heparin as the preferred anticoagulant therapy for cancer-associated VTE. However, low-molecular-weight heparin therapy has disadvantages,

Direct oral anticoagulants significantly reduced risk for recurrence of cancer-associated venous thromboembolism compared with dalteparin among patients with cancer, according to study results published in Mayo Clinic Proceedings.
The findings suggest direct oral anticoagulants (DOACs) should be considered the standard-of-care treatment for adults with cancer-associated VTE, researchers noted.
“The landmark CLOT trial established low-molecular-weight heparin as the preferred anticoagulant therapy for cancer-associated VTE. However, low-molecular-weight heparin therapy has disadvantages,